Toxic Epidermal Necrolysis
11
2
2
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
9.1%
1 terminated out of 11 trials
66.7%
-19.8% vs benchmark
9%
1 trials in Phase 3/4
100%
2 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (11)
Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis
Study To Evaluate The Efficacy Of Tofacitinib In Patients With SJS/TEN
New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies.
LYell SYndrome MEsenchymal Stromal Cells Treatment
Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis
Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study
Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis
Severe Cutaneous Adverse Reactions in Thailand
Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis
Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.
Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)